Menu Search
Equities

Niox Group PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
82C:FRA

Niox Group PLC

Actions
  • Price (EUR)0.71
  • Today's Change0.015 / 2.16%
  • Shares traded17.75k
  • 1 Year change+5.19%
  • Beta-0.0558
Data delayed at least 15 minutes, as of Feb 16 2026 10:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

NIOX Group plc is a United Kingdom-based diagnostics and management company. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX VERO is also the device of choice by clinical research organizations for respiratory studies. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company provides products and services via its direct sales organization and extensive distributor network in over 50 countries.

  • Revenue in GBP (TTM)46.00m
  • Net income in GBP4.90m
  • Incorporated2006
  • Employees84.00
  • Location
    Niox Group PLCMagdalen Centre, 1 Robert Robinson AveOXFORD OX4 4GAUnited KingdomGBR
  • Phone+44 186 540 5560
  • Fax+44 186 578 4576
  • Websitehttps://investors.niox.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.